FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890908859> ?p ?o ?g. }

• W2890908859 endingPage "448" @default.
• W2890908859 startingPage "439" @default.
• W2890908859 abstract "The response rate to therapy for rheumatoid arthritis (RA) rarely exceeds 60%. Mental disorders (MDs) of the anxiety-depressive spectrum (ADS) and cognitive impairment (CI) substantially affect the evaluation of the efficiency of RA therapy. Adequate psychopharmacotherapy is one of the possible approaches to optimizing the treatment of RA. The factors influencing the efficiency of RA therapy with standard disease-modifying antirheumatic drugs (DMARDs) and biological agents (BAs) in combination with adequate psychopharmacotherapy have not been previously identified. Objective: to determine the predictors of response to therapy in patients with RA receiving DMARDs and BAs with or without adequate psychopharmacotherapy for ADS disorders. Subjects and methods. The investigation included 128 patients (13% men and 87% women) with a reliable diagnosis of RA. At baseline, 75.1% of patients received DMARDs; 7.8% – BAs. ADS disorders were detected in 123 (96.1%) patients. Psychopharmacotherapy was offered to all the patients with MDs; 52 patients agreed to treatment and 71 refused. The following therapeutic groups were identified according to the performed therapy: 1) DMARDs (n = 39); 2) DMARDs + psychopharmacotherapy (n = 43); 3) DMARDs + BAs (n = 32); 4) DMARDs + BAs + psychopharmacotherapy (n = 9). The changes of MDs symptoms and the outcomes of RA were assessed in 83 (67.5%) patients at five-year follow-up. The efficiency of RA therapy was evaluated with DAS28 (EULAR criteria). Predictors of response to therapy were determined using linear regression modeling. Results and discussion. At 5 years, 22 (26.5%) and 37 (44.6%) patients were recorded to show good and moderate responses to therapy, respectively; 24 (28.9%) patients were non-respondents. The linear regression model included 14 factors (p<0.001). The high values of DAS28 (β=0.258) at the inclusion; belonging to therapeutic groups 2 (β=0.267), 3 (β=0.235), and 4 (β=0.210), the absence of diabetes mellitus (β=-0.230), and experience in using glucocorticoids (β=-0.230) were associated with a high likelihood of response to therapy; high body mass index (β=-0.200) and long RA duration (β=-0,181), a high level of rheumatoid factor (β=-0.176), a history of myocardial infarction (β=-0.153), schizotypic disorder (β=-0.132), and extra-articular manifestations of RA (β=-0.106), and older age (β=-0.102) were related to a low probability of response. The area under the ROC curve for the model was 0.99 (p><0.001). Conclusion. BA therapy and psychopharmacotherapy, along with younger age, shorter duration and high activity of RA, a low level of rheumatoid factor, lower body mass index, the absence of diabetes mellitus, myocardial infarction, and extra-articular manifestations of RA in the history, schizotypic disorder, and experience in using glucocorticoids are associated with a greater likelihood of a good and moderate treatment response. Keywords: rheumatoid arthritis; mental disorders; disease-modifying antirheumatic drugs; biological agents; efficiency of therapy; predictors; psychopharmacotherapy; therapy adherence><0.001). The high values of DAS28 (β=0.258) at the inclusion; belonging to therapeutic groups 2 (β=0.267), 3 (β=0.235), and 4 (β=0.210), the absence of diabetes mellitus (β=-0.230), and experience in using glucocorticoids (β=-0.230) were associated with a high likelihood of response to therapy; high body mass index (β=-0.200) and long RA duration (β=-0,181), a high level of rheumatoid factor (β=-0.176), a history of myocardial infarction (β=-0.153), schizotypic disorder (β=-0.132), and extra-articular manifestations of RA (β=-0.106), and older age (β=-0.102) were related to a low probability of response. The area under the ROC curve for the model was 0.99 (p<0.001). Conclusion. BA therapy and psychopharmacotherapy, along with younger age, shorter duration and high activity of RA, a low level of rheumatoid factor, lower body mass index, the absence of diabetes mellitus, myocardial infarction, and extra-articular manifestations of RA in the history, schizotypic disorder, and experience in using glucocorticoids are associated with a greater likelihood of a good and moderate treatment response. Keywords: rheumatoid arthritis; mental disorders; disease-modifying antirheumatic drugs; biological agents; efficiency of therapy; predictors; psychopharmacotherapy; therapy adherence><0.001). Conclusion. BA therapy and psychopharmacotherapy, along with younger age, shorter duration and high activity of RA, a low level of rheumatoid factor, lower body mass index, the absence of diabetes mellitus, myocardial infarction, and extra-articular manifestations of RA in the history, schizotypic disorder, and experience in using glucocorticoids are associated with a greater likelihood of a good and moderate treatment response." @default.
• W2890908859 created "2018-09-27" @default.
• W2890908859 creator A5025571250 @default.
• W2890908859 creator A5028988337 @default.
• W2890908859 creator A5034760786 @default.
• W2890908859 creator A5036596091 @default.
• W2890908859 creator A5063590940 @default.
• W2890908859 creator A5082471558 @default.
• W2890908859 creator A5023928252 @default.
• W2890908859 date "2018-09-08" @default.
• W2890908859 modified "2023-10-16" @default.
• W2890908859 title "FACTORS INFLUENCING THE EFFICIENCY OF THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS: THE ROLE OF COMORBID MENTAL AND SOMATIC DISEASES" @default.
• W2890908859 cites W1937148812 @default.
• W2890908859 cites W1963898345 @default.
• W2890908859 cites W1968237081 @default.
• W2890908859 cites W2000905503 @default.
• W2890908859 cites W2001917088 @default.
• W2890908859 cites W2009481513 @default.
• W2890908859 cites W2010247870 @default.
• W2890908859 cites W2071638854 @default.
• W2890908859 cites W2075687138 @default.
• W2890908859 cites W2102511154 @default.
• W2890908859 cites W2106169115 @default.
• W2890908859 cites W2106962952 @default.
• W2890908859 cites W2122000071 @default.
• W2890908859 cites W2126046176 @default.
• W2890908859 cites W2128952811 @default.
• W2890908859 cites W2131823335 @default.
• W2890908859 cites W2141706104 @default.
• W2890908859 cites W2143632050 @default.
• W2890908859 cites W2160070901 @default.
• W2890908859 cites W2166281097 @default.
• W2890908859 cites W2211818722 @default.
• W2890908859 cites W2283130396 @default.
• W2890908859 cites W2287283884 @default.
• W2890908859 cites W2327848392 @default.
• W2890908859 cites W2339335481 @default.
• W2890908859 cites W2344293580 @default.
• W2890908859 cites W2507839679 @default.
• W2890908859 cites W2511534341 @default.
• W2890908859 cites W2528566592 @default.
• W2890908859 cites W2565294726 @default.
• W2890908859 cites W2581623068 @default.
• W2890908859 cites W2582387268 @default.
• W2890908859 cites W2588266087 @default.
• W2890908859 cites W2602256766 @default.
• W2890908859 cites W2620814668 @default.
• W2890908859 cites W2621005015 @default.
• W2890908859 cites W2725127520 @default.
• W2890908859 cites W2735542462 @default.
• W2890908859 cites W2756992703 @default.
• W2890908859 cites W2766707943 @default.
• W2890908859 cites W2789480986 @default.
• W2890908859 cites W2917800966 @default.
• W2890908859 cites W4211111012 @default.
• W2890908859 cites W4233264172 @default.
• W2890908859 doi "https://doi.org/10.14412/1995-4484-2018-439-448" @default.
• W2890908859 hasPublicationYear "2018" @default.
• W2890908859 type Work @default.
• W2890908859 sameAs 2890908859 @default.
• W2890908859 citedByCount "7" @default.
• W2890908859 countsByYear W28909088592019 @default.
• W2890908859 countsByYear W28909088592020 @default.
• W2890908859 countsByYear W28909088592021 @default.
• W2890908859 countsByYear W28909088592022 @default.
• W2890908859 countsByYear W28909088592023 @default.
• W2890908859 crossrefType "journal-article" @default.
• W2890908859 hasAuthorship W2890908859A5023928252 @default.
• W2890908859 hasAuthorship W2890908859A5025571250 @default.
• W2890908859 hasAuthorship W2890908859A5028988337 @default.
• W2890908859 hasAuthorship W2890908859A5034760786 @default.
• W2890908859 hasAuthorship W2890908859A5036596091 @default.
• W2890908859 hasAuthorship W2890908859A5063590940 @default.
• W2890908859 hasAuthorship W2890908859A5082471558 @default.
• W2890908859 hasBestOaLocation W28909088591 @default.
• W2890908859 hasConcept C118552586 @default.
• W2890908859 hasConcept C126322002 @default.
• W2890908859 hasConcept C1862650 @default.
• W2890908859 hasConcept C198451711 @default.
• W2890908859 hasConcept C2776999253 @default.
• W2890908859 hasConcept C2777575956 @default.
• W2890908859 hasConcept C558461103 @default.
• W2890908859 hasConcept C71924100 @default.
• W2890908859 hasConceptScore W2890908859C118552586 @default.
• W2890908859 hasConceptScore W2890908859C126322002 @default.
• W2890908859 hasConceptScore W2890908859C1862650 @default.
• W2890908859 hasConceptScore W2890908859C198451711 @default.
• W2890908859 hasConceptScore W2890908859C2776999253 @default.
• W2890908859 hasConceptScore W2890908859C2777575956 @default.
• W2890908859 hasConceptScore W2890908859C558461103 @default.
• W2890908859 hasConceptScore W2890908859C71924100 @default.
• W2890908859 hasIssue "4" @default.
• W2890908859 hasLocation W28909088591 @default.
• W2890908859 hasOpenAccess W2890908859 @default.
• W2890908859 hasPrimaryLocation W28909088591 @default.
• W2890908859 hasRelatedWork W1527365325 @default.
• W2890908859 hasRelatedWork W1986660814 @default.
• W2890908859 hasRelatedWork W2007814833 @default.

• next